Released on: October 31, 2008, 5:45 am

Press Release Author: Drug Safety Alliance

Industry: Pharmaceuticals

Press Release Summary: Information Technology Improvements Support Implementation of
Enhanced Adverse Event Reporting Software

Press Release Body: (Research Triangle Park, N.C.) - October 30, 2008 -- Drug Safety
Alliance (DSA), a global leader in pharmaceutical safety and pharmacovigilance,
today announced major hardware and software upgrades to support the implementation
of the new Empirica (TM) Trace adverse event reporting software. The announcement
was made as DSA Chief Information Officer Doug Hill presented a case study on the
upgrade at the Seventh Annual International Users Conference in San Francisco
sponsored by Phase Forward, developers of the software.

Drug Safety Alliance is one of the first companies utilizing Empirica (TM) Trace,
which allows pharmaceutical drug developers and other DSA clients to collect, code,
analyze, and report adverse events during clinical trials and post-marketing to meet
regulatory reporting requirements in the United States and overseas. The new
software replaces Clintrace (TM), a previous version of the software utilized by
DSA.

"This upgrade to support Empirica (TM) Trace will add convenience, security, and
uptime while enabling us to improve efficiency," said Hill, adding clients will
notice improvements at the user level such as an improved electronic submissions
module.

According to Hill, DSA started working with Phase Forward in November of 2007 on
issues such as moving to windows authentication and performing necessary hardware
changes, having performed risk and gap analysis on the software in April of this
year.

"I'm proud of the work our team has done to take this technology to the next level,"
said Cathy Stokes, CEO of Drug Safety Alliance.

In addition to employing secure, state-of-the-art information technology
infrastructure to support database mining, collection and reporting software like
Empirica (TM) Trace, DSA's information technology department provides data
consolidation services and offers secure database hosting options, acting as a
virtual IT department for clients. The IT services offered by DSA complement the
company's well-established pharmacovigilance practices.

About Drug Safety Alliance
Founded in 2000, Drug Safety Alliance (DSA) provides pharmacovigilance expertise to
large and small pharmaceutical and biotechnology companies to help them develop safe
drugs and improve patient safety. DSA's mission is to partner with clients to
mitigate their drug safety risks and to maximize product longevity and value. Driven
by the highest ethical standards, DSA is uniquely focused to provide high-quality
pre- and post-market drug safety services including domestic and international
regulatory compliance, safety database support and hosting options, risk management
and adverse event case management. DSA is headquartered in the Research Triangle
Park region of North Carolina with strategic partnerships worldwide. For more
information please visit www.DrugSafetyAlliance.com.


Web Site: http://www.drugsafetyalliance.com

Contact Details: David Menzies
Menzies Consulting, Inc
dmenzies@menziesconsulting.com
(919) 274-6862